



Gunderson Dettmer Advises Vir Biotechnology on Underwritten Public Offering

Client News

February 25, 2026

Gunderson Dettmer represented Vir Biotechnology in its underwritten public offering of 20,294,117 shares of common stock at \$8.50 per share, including the exercise in full of the underwriters' option to purchase additional shares.

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.

The gross proceeds from the offering are expected to be \$172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. Vir Biotechnology sold all of the shares in the offering, which closed on February 27, 2026.

The Gunderson deal team was led by Public Companies/Public Offerings partners Jeff Vetter and Alexa Belonick and included Public Companies/Public Offerings associates Daniel Reichert, Michael Tiab, and Lydia Wang, tax partner Jace Clegg, and senior paralegal Scott Paraker.

Related People

Jeffrey R. Vetter

PARTNER

P +1 650 321 2400

Alexa Belonick
PARTNER
P +1 415 801 4940

Daniel Reichert
ASSOCIATE
P +1 650 463 5219

Michael S. Tiab
ASSOCIATE
P 415-801-4826

Jace E. Clegg
PARTNER
P +1 646 490 9040

Related Services

Life Sciences
Private & Public Companies
Public Companies/Public Offerings

Featured Insights

CLIENT NEWS
Elly Launches With \$8 Million Pre-Seed Financing

CLIENT NEWS
Slang AI Announces \$36 Million Series B

CLIENT NEWS
Aalyria Reaches \$1.3 Billion Valuation With \$100 Million Series B

INSIGHTS
Law360 Interviews Stephanie Goutos in “Meet The Attys ‘Vibe-Coding’ Their
Own AI Apps”

Own AI Apps

PUBLIC VENTURES

'A New Day for Public Companies and Their Investors': SEC CorpFin Director Previews Aggressive Rulemaking Agenda

CLIENT NEWS

Kavak Announces \$300 Million Series F

CLIENT NEWS

Ever Emerges From Stealth With \$31 Million Series A

INSIGHTS

Client Insight: Annual Reminders: Securities Filings (Schedule 13D / Form 13F / Schedule 13G Filings, Form 13H Annual Update Filings), Privacy Notices and Policy Updates, Form ADV Updating Amendment Requirements, CA Venture Diversity Reporting

EVENTS

Webinar: 2026 Employment Law Update

CLIENT NEWS

Frontier Growth Leads Hauler Hero's \$16 Million Series A

CLIENT NEWS

Gunderson Dettmer Represents Ollie Pets in Acquisition by Agrolimen

INSIGHTS

2026 AI Laws Update: Key Regulations and Practical Guidance